Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Neurology Phase II
Denmark 
Details:
Lu AF82422 is a human monoclonal antibody (mAb) targeting the toxic alpha-synuclein protein known to be a pathological hallmark of MSA. The compound is thought to work like the body’s natural immune system to clear these harmful proteins.
Lead Product(s): Lu AF82422
Therapeutic Area: Neurology Product Name: Lu AF82422
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
The phase IIa study of Lundbeck's selective positive allosteric modulator of the glutamate 4 receptor, foliglurax, for the treatment of Parkinson's disease did not meet the primary study endpoint.
Lead Product(s): Foliglurax
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
Details:
Insufficient efficacy to proceed with development of Lu AG06466 in Tourette Syndrome, However, safety and tolerability of the agent allows for further studies in additional indications will proceed.
Lead Product(s): Lu AG06466
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2020
